The location of HIV integration sites is thought to play a critical role in the clonal expansion of infected cells and HIV persistence. Cell culture models are often used to study and assess HIV latency and latency-reversing agents, but it is unclear how these models reflect HIV integration in vivo. We have developed a high-throughput sequence-capture assay to evaluate the integration site characteristics of 3 cellular models.
Integration site analysis was performed in three cellular models of HIV persistence: ACH-2 cells, Bcl-2 transduced primary CD4+ cells, and cells from a cultured TCM model. A clonal population of ACH-2 cells was also included after limiting dilution and expansion with ART. Sequence enrichment was performed with a diverse biotinylated probe library composed of 52 consensus probe sequences designed using the LANL database. Libraries were sequenced on the MiSeq platform (Illumina) with 300 bp paired-end reads. Sites were annotated with UCSC canonical gene annotations and gene ontology analysis was performed using the Gene SeT Analysis Toolkit. Genes identified from the cellular models were also compared to highly represented genes from two previously published patient datasets.
While ACH-2 cells are historically thought to have a single site of integration, we identified two main integration sites. In addition, we found that 47% of reads were outside of the two major integration sites. Integration site analysis of the clonal ACH-2 population showed near elimination of single integration sites (ACH-2 bulk culture vs. ACH-2 clone: 39.4% vs. 0.2%, Fisher’s P <0.01), suggesting that this assay has an extremely low false-positive rate and confirming the diversity of integration sites within the ACH-2 population. Across the 3 cellular models, there were significant differences in integration site characteristics, including the proportion of clonally-expanded sites, sites within genic regions, exons, and the orientation of the integrated HIV relative to the host gene. Gene ontology analysis of highly represented genes from the patient samples found little overlap with HIV-containing genes from the cell lines.
Integration site differences exist amongst the commonly used cellular models of HIV persistence and in comparison to integration sites found in patient samples. These results may contribute to differences seen in the response to latency-reversing agents amongst cellular models and patient-derived cells.